Lexeo Therapeutics
https://www.lexeotx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lexeo Therapeutics
In Vivo’s 2022 Rising Leaders: Putting A Spotlight On Talent
The third annual listing of In Vivo’s ‘Rising Leaders’ includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.
Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Stelios Therapeutics, Inc.